Want to see TSE:CPH full AI Analyst Report?
CPH Stock Chart & Stats
C$16.25
-C$0.19(-1.16%)
At close: 4:00 PM EDT
C$16.25
-C$0.19(-1.16%)
Day’s Range― - ―
52-Week RangeC$12.48 - C$20.56
Previous CloseN/A
Volume9.58K
Average Volume (3M)26.25K
Market Cap
C$363.69M
Enterprise ValueC$420.80
Total Cash (Recent Filing)C$9.10M
Total Debt (Recent Filing)C$366.40K
Price to Earnings (P/E)9.1
Beta0.90
Next Earnings
Nov 05, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.14
Shares Outstanding25,415,071
10 Day Avg. Volume28,238
30 Day Avg. Volume26,255
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$20.00Price Target Upside23.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.81
Revenue Forecast (FY)C$53.46M
Bulls Say, Bears Say
Bulls Say
High Margins And Operating EfficiencyExceptionally high gross and EBITDA margins provide resilience against product volatility. The 6% YTD EBITDA increase, despite lower revenue, indicates that cost control and operating efficiency can protect profitability over the next several quarters.
Debt-Free Balance Sheet And Cash GenerationA debt-free balance sheet and positive operating cash flow give Cipher flexibility to fund commercialization, withstand product-specific setbacks, and pursue acquisitions or licensing without immediate dependence on equity issuance or expensive borrowing.
Epuris Market Share And Reimbursement ExpansionEpuris combines established Canadian leadership with growing volume and a potential reimbursement expansion. Broader public-plan access could enlarge the addressable patient base, improve prescribing economics, and support durable share gains.
Bears Say
Natroba U.S. Revenue PressureNatroba is facing a structural channel challenge rather than a one-day disruption. Reduced Medicaid volumes pressure the company’s U.S. revenue base, while new direct-to-patient and retail channels will require execution and time to offset the decline.
Declining Top-Line And Licensing RevenueRevenue contraction across both direct product sales and licensing indicates that growth is not yet broad-based. Lower partner shipments also expose earnings to commercialization timing and partner demand, making future top-line recovery less predictable.
Uncertain Business-Development PipelineCipher’s acquisition and licensing model depends on replenishing and expanding its product portfolio. Uncertain deal timing, combined with the abandoned opportunity, could delay diversification and leave results more dependent on the existing Natroba and Epuris base.
Cipher Pharmaceuticals News
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$12.48 and its highest was C$20.56 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is C$363.69M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 78 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported C$0.209 earnings per share for the quarter, missing the consensus estimate of C$0.287 by -C$0.078.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.29.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,415,071 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.209 in its last earnings report, missing expectations of C$0.287. Following the earnings report the stock price went down -21.393%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$20.00 (23.08% Upside)
C$20.00 (23.08% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
CPH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a cautiously positive outlook: while the U.S. business (Natroba) experienced clear top-line pressure—driving a 10% decline in quarter revenue and a 19% decline in Natroba sales versus prior year—the company offset those headwinds with strong margin performance, SG&A reductions, cash generation, year-to-date EBITDA growth (+6% YTD), and concrete commercial and reimbursement progress for Epuris (14% revenue growth, expanded pCPA LOI and 47.1% market share). Management laid out actionable mitigation plans for U.S. channel diversification (DTC, retail, delivery), maintained an opportunistic M&A/in-licensing posture, and preserved liquidity and financing optionality. Overall, positives (sustained high margins, Epuris momentum, cost efficiencies, solid cash and financing capacity) meaningfully outweigh the operational revenue setbacks in the quarter.View all TSE:CPH earnings summariesCPH Stock 12 Month Forecast
Average Price Target
C$20.00
▲(23.08% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―